Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy

Abstract

Sarcopenia (≥15.0% loss of IM from baseline) was revealed to be an important prognostic factor in patients with CC undergoing CCRT.

Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer

“…Evaluating muscle at a single specific time point may not help in predicting survival and could not evaluate muscle loss . These findings suggested that a longitudinal study of changes in body composition may provide a more comprehensive understanding of the impacts of body composition on outcomes …”

“…49,62 These findings suggested that a longitudinal study of changes in body composition may provide a more comprehensive understanding of the impacts of body composition on outcomes. [40][41][42][43][44][45][46][47][48][49] Body mass index is an imprecise measure of body composition, and monitoring BMI changes may be insufficient to promptly identify occult body composition changes. 18,19 We found that changes in SMI and TATI were weakly correlated with the change in BMI, and changes in SMD and SMG showed no correlation with the BMI.…”

“…[35][36][37] Sarcopenia and myosteatosis at the time of cancer diagnosis were previously shown to be associated with the outcome in EC. 38,39 A longitudinal study of changes in body composition during cancer therapy may provide a more comprehensive understanding of the influences of body composition on cancer outcomes [40][41][42][43][44][45][46][47][48][49][50][51] ; however, the changes in body composition during cancer therapy and its impact on outcomes in stage III EC patients were unclear. Moreover, current doses of chemotherapy are calculated based on body surface area (BSA), which takes only height and weight into account and not other potentially important body composition parameters.…”

Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer

“…Adiposity was also an independent prognostic factor of outcomes according to three recent large studies (19)(20)(21). Longitudinal studies of body composition change during treatment (15)(16)(17)(18) may provide a more comprehensive picture of how body composition is associated with outcomes. However, there is a paucity of data on the potential effect of skeletal muscle and adipose tissue change during CCRT on the outcomes of patients with LACC.…”

“…During the course of CCRT, gastrointestinal toxicities could potentially contribute to weight loss, nutrient malabsorption, and even malnutrition in these patients (4,5); therefore, the body composition including skeletal muscle and adipose tissue might change during CCRT, and this change could play a role in cancer outcomes (6,7). Emerging evidence suggests that sarcopenia is associated with a poor prognosis and increased treatment-related toxicities in patients with metastatic and non-metastatic cancers (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). Adiposity was also an independent prognostic factor of outcomes according to three recent large studies (19)(20)(21).…”